Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Blood Clotting Linked to Immune Response

By BiotechDaily International staff writers
Posted on 25 Apr 2013
A link has been discovered between a protein that triggers the formation of blood clots and other proteins that are essential for the body's immune system.

Vascular endothelial cells express and release protein components of the complement pathways, as well as secreting and anchoring ultra-large von Willebrand factor (ULVWF) multimers in long, string-like structures that initiate platelet adhesion during hemostasis and thrombosis.

Scientists at Rice University (Houston, TX, USA) quantified gene expression of complement components in cultured human umbilical vein endothelial cells by real-time polymerase chain reaction (PCR). They used fluorescent microscopy, monospecific antibodies against complement components, and fluorescent secondary antibodies.

Goat polyclonal antibodies to individual human complement components, purified human complement proteins, and human sera depleted of each specific complement factor were obtained from Complement Technology (Tyler, TX, USA). Monospecific reactivity of each complement antibody was verified by Western blotting.

The investigators established a biochemical link between clotting and the body's immune response involved a key clotting protein called von Willebrand factor (VWF) and about a dozen other proteins that are components of the complement system. The complement system, a part of the body's innate immune system, is one of biology's most ancient forms of defense against invading pathogens. They found that C3, an important complement pathway-initiator protein, was produced by cells in such low concentration that it was almost impossible to see, even with a fluorescent microscope, but that changed when they looked at samples that contained both C3 and VWF.

Joel Moake, MD, a hematologist and senior author of the study said, "In addition to the clinical evidence, there's also a logical basis for this connection. Clotting is a type of wound response, and wounds are magnets for infection, so there could be a selective advantage in triggering both responses at the same time. This link opens the door for studying severe, debilitating inflammatory disorders where the disease mechanism is still poorly understood, including lupus, rheumatoid arthritis, regional ileitis and ulcerative colitis, as well as age-related macular degeneration." The study was published on March 29, 2013, in the journal Public Library of Science ONE.

Related Links:

Rice University
Complement Technology




Channels

Genomics/Proteomics

view channel
Image: The photomicrograph shows the head of a mouse embryo in which the pericytes are visible as blue dots along the blood vessel (Photo courtesy of the University of Gothenburg).

Genetically Engineered Mouse Model Reveals Key to Formation of the Blood-Brain Barrier

Use of a mouse model that had been genetically engineered to lack the gene that encodes the forkhead transcription factor Foxf2 has helped to explain how pericytes, cells that line the capillaries, form... Read more

Drug Discovery

view channel
Image: Scanning electron microscope (SEM) image of a field of polypyrrole nanowires (Photo courtesy of Dr. Richard Borgens, Purdue University).

Novel Controlled-Release Drug Delivery System Heals Spinal Inflammation in Mouse Model

A novel drug delivery system that allows controllable release of an anti-inflammatory agent directly to the site of inflammation or injury was tested successfully in a mouse model. Investigators at... Read more

Business

view channel

Biopharm Startup to Commercialize Antibody Therapy for Drug Resistant Cancers

A biopharm startup company has licensed the rights to commercialize an antibody-based approach for treatment of drug resistant cancers. The new company, CadheRx Therapeutics (La Jolla, CA, USA), entered into a licensing agreement with Stony Brook University (NY, USA) to develop and market an anticancer technology derived... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.